venlaxafine

Trade name: Effexor

Small moleculeapproved

Approved

Jun 1, 1993

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD) as a recommended first-line treatment. It may also be used for chronic neuropathic pain. It is taken orally. It is also available as the salt venlafaxine besylate in an extended-release formulation. — Wikipedia

Clinical trial activity

6 trials · 8 clinical orgs · 1 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
1

Earliest trial started Jan 1, 2002 (NCT01352572)

Timeline

1990s

  1. Jun 1, 1993

    Earliest FDA Approval

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jun 29, 2022

    Alvogen — First NDA Organization

  2. Jun 29, 2022

    Alvogen — Marketing Organization

  3. Jun 29, 2022

    Alvogen — NDA Secondary Org

  4. Jun 29, 2022

    Alvogen — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedJun 1, 1993

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.O=S(=O)(O)c1ccccc1
Mol. weight
435.59 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • venlaxafine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03538691Phase 3Jul 13, 2018Otsuka
NCT03434041Phase 3May 25, 2018Johnson and Johnson
NCT01557712Phase 3Mar 1, 2012University of Grenoble
NCT00974155Phase 4Sep 1, 2009German Federal Ministry of Education and Research, Johannes Gutenburg University
NCT00612807Phase 1/Phase 2 (Phase 2)Jul 1, 2006Duke University, National Institutes of Health (NIH)
NCT01352572N/AJan 1, 2002Sungkyunkwan University
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Duke UniversityAcademic/Hospital1112006
German Federal Ministry of Education and ResearchGovernment1012009
Johannes Gutenburg UniversityAcademic/Hospital1112009
Johnson and JohnsonFor profit1112018
National Institutes of Health (NIH)Government1012006
OtsukaFor profit1112018
Sungkyunkwan UniversityAcademic/Hospital1112002
University of GrenobleAcademic/Hospital1112012
8 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
AlvogenFor profitMKTGJun 29, 2022
AlvogenFor profitNDA2Jun 29, 2022
AlvogenFor profitNDAJun 29, 2022